Vectura’s Inhalation Center of Excellence Granted Planning Permission
On 31 March 2022, both Will Downie and Paul Fry stepped down from their respective roles as Chief Executive Officer and Chief Financial Officer at Vectura. Under their leadership, Vectura [plc] made significant progress towards its transformation, and today Vectura is recognised as, a valued partner in the pharmaceutical industry for the development of inhaled therapeutic products.
We are immensely proud to have been awarded Best Communication Award at the European Mediscience Awards. The judges concluded that 2020/21 were significant years of progress for Vectura, under our new inhalation contract development and manufacturing organisation (CDMO) strategy
Vectura Group faces a growing backlash over its acquisition by a tobacco company, with some doctors and patients signalling they may switch to treatments made by rivals such as AstraZeneca and Teva Pharmaceutical Industries.
Asthma inhaler maker Vectura has been excluded from a pharmaceutical conference after academics staged a rebellion over the company’s £1.1bn takeover by cigarette company Philip Morris International (PMI).
Tobacco giant Philip Morris International (PMI) has clinched shareholder backing for its controversial £1.1bn takeover of asthma inhaler maker Vectura.
The tobacco company Philip Morris International (PMI) has sealed its controversial £1.1bn takeover of the asthma inhaler maker Vectura, after more than half of the target company’s shareholders agreed to sell their stock.
PMI revealed it now has support from investors representing 74% of Vectura shareholders - above the 50% threshold for the deal to go through - and is urging the remaining shareholders to accept the deal.
Sharon Johnson, Executive Vice President – Delivery Management, shared her views in a main feature in August’s edition of The Medicine Maker. In the piece, headlined ‘So, you want to become a CDMO…’ Sharon explores what to keep in mind when pivoting a business to provide drug development services to customers.
About a week after Vectura’s board of directors said they would unanimously back a Philip Morris takeover, the tobacco giant now has control of more than a fifth of the respiratory drugmaker’s shares.